ライフサイエンスコーパス: ibandronate

1 4 to 0.949 +/- 0.027 g/cm(2), P < 0.001 with ibandronate).

2 nd the amino bisphosphonates alendronate and ibandronate.

3 decreased osteoblast numbers in response to ibandronate.

4 results, a relatively high concentration of ibandronate (100 microM) increased caspase-3 activity an

5 e efficacy, adherence, and safety of monthly ibandronate (150 mg) with weekly alendronate (70 mg) wer

6 Treatment with ibandronate (4 micrograms per mouse per day) significant

7 dose-dense chemotherapy regimens and 2:1 to ibandronate 50 mg per day orally for 2 years or observat

8 ne response of mice chronically treated with ibandronate, a commonly used bisphosphonate.

9 Furthermore, ibandronate also significantly decreased the MDA-231 tum

10 in-of-function mutants are also resistant to ibandronate, an inhibitor of an enzyme downstream of HMG

11 08, 2,015 patients were randomly assigned to ibandronate and 1,008 to observation.

12 The investigational bisphosphonates ibandronate and zoledronic acid may offer the advantage

13 es of AMD reported with alendronate, 20 with ibandronate, and 14 with risedronate.

14 reported odds ratios (RORs) for alendronate, ibandronate, and risedronate were 3.82 (95% CI: 2.94-4.9

15 for treatment of osteoporosis (alendronate, ibandronate, and risedronate) and treatment/prevention o

16 Adjuvant treatment with oral ibandronate did not improve outcome of patients with hig

17 However, ibandronate did not prevent the mice from developing hin

18 In contrast, ibandronate failed to inhibit MDA-231 tumor formation wi

19 n increase in disease-free survival (DFS) by ibandronate from 75% to 79.5% by using a two-sided alpha

20 Thirty-three patients, 14 in the ibandronate group and 19 in the alendronate group, compl

21 a combination therapy of low dose parenteral ibandronate (IBN) and calcitriol on top of calcium and v

22 oth regimens, weekly alendronate and monthly ibandronate, improve bone mass and are comparable in saf

23 ned the effects of the potent bisphosphonate ibandronate in a murine model of human myeloma bone dise

24 s, suggesting an involvement of caspase-3 in ibandronate-induced apoptosis.

25 , z-Val-Ala-Asp-fluoromethyl ketone, blocked ibandronate-induced DNA fragmentation in MDA-231 cells,

26 Ibandronate is an orally and intravenously available ami

27 These data suggest that the effects of ibandronate on apoptosis in MDA-231 breast cancer cells

28 Here we examined the effects of the BP ibandronate on MDA-231 human breast cancer cells in bone

29 There was no significant effect of ibandronate on total myeloma cell burden, as assessed by

30 been inhibited by concurrent treatment with ibandronate or osteoprotegerin.

31 e either been recently released (intravenous ibandronate), or have completed (zoledronic acid) or are

32 e either been recently released (intravenous ibandronate), or have completed (zoledronic acid) or are

33 Adherence to therapy was higher with ibandronate (P = 0.009).

34 oma and breast and prostate cancer patients (ibandronate, pamidronate, and zoledronic acid).

35 istomorphometrical examination revealed that ibandronate reduced osteoclastic bone resorption, with i

36 Interestingly, ibandronate reduced the numbers of megakaryocytes, a kno

37 dence suggests that alendronate, etidronate, ibandronate, risedronate, zoledronic acid, estrogen, par

38 cancer cells are restricted in bone in which ibandronate selectively deposits.

39 Patients randomly assigned to ibandronate showed no superior DFS or overall survival (

40 However, there, ibandronate shunted the homing of bone marrow plasma cel

41 treatment with the bisphosphonate compound, ibandronate, significantly delayed the progression of os

42 ers were then observed in the spleens of the ibandronate-treated mice.

43 also responded normally to immunization when ibandronate was applied to naive mice.

44 When ibandronate was injected into mice after a primary immun

45 DFS was numerically longer if ibandronate was used in patients younger than 40 years o

46 Ibandronate, which was administered (s.c. daily; 4 micro

47 We report here the efficacy analysis for ibandronate, which was released by the independent data